Clinical trials: T-cell Lymphoblastic Lymphoma
Leukemia, Lymphoma
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006042
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Giving high doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00521261
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphoma, B-Cell, Acute Lymphoblastic Leukemia, Pediatric
CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
This study seeks to examine the efficacy and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor (CAR) targeting the B cell surface antigen CD19…
- Trial name
- NCT06866873
- Testing
- CAR-T
- Where
- Hong Kong
- Volunteers
- 18 people
- Sponsor
- Hong Kong Children's Hospital
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B cell acute lymphoblastic…
- Trial name
- NCT04404660
- Testing
- AUTO1
- Where
- 34 sites in United States, Spain and 1 more
- Volunteers
- 153 people
- Sponsor
- Autolus Limited
Non-Hodgkin's Lymphoma, Multiple
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
This study uses a drug called dasatinib to produce an anti-cancer effect called large granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as natural killer cells that remove cancer cells.
- Conditions
- Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Lymphoma
- Trial name
- NCT01609816
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Acute, Leukemia, T Cell
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
ETP-ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this…
- Conditions
- Leukemia, Acute, Leukemia, T Cell, Leukemia, Lymphoblastic
- Trial name
- NCT03553238
- Testing
- Chidamide, Dexamethasone, vincristine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.
- Conditions
- Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin, Relapsed Refractory Multiple Myeloma
- Trial name
- NCT06783816
- Testing
- chimeric antigen receptor gene modified T cells
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanxi Bethune Hospital
B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 in paediatric or young adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia
- Trial name
- AMELIA (NCT03289455)
- Testing
- AUTO3 (CD19/22 CAR T cells
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Autolus Limited
Cancer
Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer
RATIONALE: Learning about the amount of information on fertility and infertility by patients before they received treatment for cancer in a comprehensive cancer center may help doctors plan the best treatment.
- Trial name
- NCT01295463
- Testing
- questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut Català d'Oncologia
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission
Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate
This laboratory study is looking at response or resistance to chemotherapy in young patients with acute lymphoblastic leukemia treated with methotrexate.
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00898404
- Testing
- laboratory biomarker analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL
T cell acute lymphoblastic leukemia (T-ALL)/Lymphoblastic lymphoma (LBL) is a hematological malignancy caused by malignant transformation and clonal expansion of T-lineage precursor cells.
- Trial name
- NCT05598593
- Testing
- cytarabine+thiotepa+ fludarabine + busulfan
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00253552
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia, Lymphoma
506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Clinical trial to study the effectiveness of 506U78 in treating patients who have relapsed or…
- Trial name
- NCT00003837
- Testing
- nelarabine
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Precursor Cell Lymphoblastic Leukemia-Lymphoma
De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)
No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks, L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, T-ALL patients in complete remossion…
- Trial name
- NCT03462095
- Testing
- Autologous HSCT
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- National Research Center for Hematology, Russia
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
- Trial name
- NCT01231919
- Testing
- Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 25 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying how well rituximab works in preventing acute graft-versus-host disease (GVHD) in patients undergoing a donor stem cell transplant for hematologic cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT01044745
- Testing
- rituximab, mycophenolate mofetil, tacrolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory CD19-positive B cell Hematological Malignancies
- Trial name
- NCT06277011
- Testing
- Metabolically Armed CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Anhui Provincial Hospital
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
RATIONALE: Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00962507
- Testing
- everolimus, panobinostat, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myelodysplastic Syndromes
Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00002809
- Testing
- anti-thymocyte globulin, filgrastim, sargramostim
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Temple University
Acute Lymphoblastic Leukemia, B-precursor, Non-Hodgkin Lymphoma, B-cell
T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
This phase 1 / 2 study will evaluate the response of B-cell malignancies expressing CD19 to autologous T cells transduced with a second generation anti-CD19 chimeric antigen receptor in children and young adults.
- Trial name
- NCT02772198
- Testing
- CD19 CAR T cells
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Sheba Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.